Health care costs among renal cancer patients using pazopanib and sunitinib.

Autor:	Hansen RN; University of Washington, Box 357630, Seattle, WA 98195. rhansen@uw.edu., Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, Ramsey SD
Jazyk:	angličtina
Zdroj:	Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2015 Jan; Vol. 21 (1), pp. 37-44, 44a-d.
DOI:	10.18553/jmcp.2015.21.1.37
Abstrakt:	Background: Pazopanib was noninferior to sunitinib in progression-free survival in a phase III, open-label, randomized clinical trial comparing the efficacy and safety of the 2 drugs for treatment of patients with advanced renal cell carcinoma (RCC). A secondary analysis of this trial conducted on patient-reported health care resource utilization (HCRU) endpoints revealed significantly fewer monthly telephone consultations and emergency department visits among patients treated with pazopanib over the first 6 months of treatment. Objectives: To (a) compare total costs of HCRU and adverse events (AEs) in patients with advanced RCC receiving first-line pazopanib or sunitinib from the phase III clinical trial and (b) perform a post hoc economic analysis that applied direct medical care and pharmacy unit costs, obtained from the Truven Health MarketScan Databases, to HCRU and AE rates. Methods: Total HCRU costs included components for provider contacts, diagnostics, hospitalizations, procedures, and study/nonstudy drugs. Patients were stratified by the presence or absence of an AE in order to estimate costs attributable to AEs. Costs were adjusted to 2013 U.S. dollars. The highest 1% of cost outliers were equally excluded from each group. Univariate (t-test and Kaplan-Meier sample average [KMSA]) and multivariate (using treatment group and region as covariates) analyses were performed. Results: A total of 906 patients (pazopanib, n = 454; sunitinib, n = 452) reported HCRU; higher rates were observed for sunitinib. In unadjusted cost analyses, the mean total costs for pazopanib-treated patients were 8.0% lower than those treated with sunitinib ($80,464 vs. $86,886; P = 0.20). The difference in KMSA-estimated costs was significantly higher for sunitinib versus pazopanib ($156,128 vs. $143,585; P = 0.003). Adjusted cost differences between arms consistently suggested higher costs for sunitinib. Among patients who experienced greater than or equal to 1 AE, costs were $8,118 higher for pazopanib-treated patients and $14,343 for sunitinib-treated patients. Conclusions: The findings suggest that health care costs were lower among patients with advanced RCC treated first-line with pazopanib versus sunitinib.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu